Get the Stockscreener App
0.921
5.05%
-0.049
After Hours:
.91
-0.011
-1.19%
Pasithea Therapeutics Corp stock is traded at $0.921, with a volume of 321.94K.
It is down -5.05% in the last 24 hours and down -18.50% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.97
Open:
$0.95
24h Volume:
321.94K
Relative Volume:
0.05
Market Cap:
$21.27M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0662
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-28.60%
1M Performance:
-18.50%
6M Performance:
+27.74%
1Y Performance:
-67.11%
1-Day Range:
$0.8198
$0.95
1-Week Range:
$0.8198
$1.28
52-Week Range:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.921 | 22.40M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Why Pasithea Therapeutics Corp. stock remains undervaluedJuly 2025 Selloffs & Daily Entry Point Trade Alerts - ulpravda.ru
Why hedge funds are buying Pasithea Therapeutics Corp. stockDay Trade & Expert Curated Trade Ideas - ulpravda.ru
How Pasithea Therapeutics Corp. stock benefits from strong dollar2025 Risk Factors & Short-Term High Return Ideas - ulpravda.ru
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pasithea Therapeutics Corp Stock Analysis and ForecastMomentum Trading Signals & Big Profit Low Capital - earlytimes.in
How Pasithea Therapeutics Corp. stock compares to industry benchmarks2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Can Pasithea Therapeutics Corp. stock hit analyst price targetsWeekly Stock Analysis & Safe Entry Momentum Stock Tips - Улправда
What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock cheap at current valuationTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
What is the fair value of Pasithea Therapeutics Corp. Equity Warrant stock nowQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock a dividend growth opportunityJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - Улправда
Will Pasithea Therapeutics Corp. stock return to pre crisis levelsWeekly Investment Report & Fast Gaining Stock Strategy Reports - Улправда
What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stockLong Setup & Accurate Entry and Exit Point Alerts - Улправда
Recap Report: What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockTrade Analysis Report & Daily Oversold Stock Bounce Ideas - Улправда
Pasithea Therapeutics Regains Nasdaq Compliance - theglobeandmail.com
Pasithea Therapeutics regains Nasdaq compliance - MSN
Pasithea Therapeutics regains Nasdaq compliance with minimum bid price rule - Investing.com
Pasithea Therapeutics (NASDAQ: KTTA) back in Nasdaq bid price compliance - Stock Titan
Market Review: Is Pasithea Therapeutics Corp stock a contrarian buy2025 Top Gainers & Safe Capital Allocation Plans - moha.gov.vn
LEAHY EMER Insider Trades - Nasdaq
SCHNEIDERMAN DANIEL H Insider Trades - Nasdaq
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Pasithea Therapeutics Corp - GuruFocus
Pasithea Therapeutics (NASDAQ:KTTA) Upgraded at Zacks Research - Defense World
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
What is HC Wainwright’s Forecast for KTTA FY2025 Earnings? - Defense World
HC Wainwright Begins Coverage on Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
There is no way Pasithea Therapeutics Corp (KTTA) can keep these numbers up - setenews.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target - marketscreener.com
MSN Money - MSN
Is Pasithea Therapeutics Corp. stock attractive for hedge funds2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Small Cap Stocks To ConsiderNovember 30th - MarketBeat
Will Pasithea Therapeutics Corp. Equity Warrant stock benefit from commodity prices2025 Dividend Review & Weekly Top Performers Watchlists - Newser
Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10% - Yahoo Finance
Pasithea Therapeutics Reaches US$104m Market Cap Benefiting Insider Stock Buying - simplywall.st
Lawrence Steinman Bought 201% More Shares In Pasithea Therapeutics - Yahoo Finance
Pasithea Therapeutics Completes $60M Public Offering - MSN
Will Pasithea Therapeutics Deliver On Clinical Promise Or Struggle With Funding Risks? - RTTNews
Small Cap Stocks To Follow NowNovember 29th - MarketBeat
Best Small Cap Stocks To Keep An Eye OnNovember 28th - MarketBeat
Best Penny Stocks To Watch TodayNovember 29th - MarketBeat
Pasithea Therapeutics announces closing of $60 million public offering of common stock - marketscreener.com
Pasithea Therapeutics (Nasdaq: KTTA) raises $60M, extends cash runway into 2028 - Stock Titan
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):